A review of emerging neuroprotective and neuroregenerative therapies in traumatic spinal cord injury.


Journal

Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133

Informations de publication

Date de publication:
10 2021
Historique:
received: 09 04 2021
accepted: 04 08 2021
pubmed: 15 9 2021
medline: 9 11 2021
entrez: 14 9 2021
Statut: ppublish

Résumé

Traumatic spinal cord injuries (SCIs) have far-reaching physical, social, and financial consequences. While medical advancements have improved supportive therapeutic measures for SCI patients, no effective neuroregenerative therapeutic options exist to date. Instead, the paradigm of SCI therapy is inevitably directed towards damage control rather than the restoration of a state of functional independence. Facing a continuous increase in the prevalence of spinal cord injured patients, neuroprotective and neuroregenerative strategies have earned tremendous scientific interest. This review intends to provide a robust summary of the most promising neuroprotective and neuroregenerative therapies currently under investigation. While we highlight encouraging neuroprotective strategies as well, the focus of this review lies on neuroregenerative therapies, including neuropharmacological and cell-based approaches. We finally point to the exciting investigational areas of biomaterial scaffolds and neuromodulation therapies.

Identifiants

pubmed: 34520943
pii: S1471-4892(21)00130-2
doi: 10.1016/j.coph.2021.08.009
pii:
doi:

Substances chimiques

Neuroprotective Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-340

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Nader Hejrati (N)

Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada.

Michael G Fehlings (MG)

Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. Electronic address: Michael.Fehlings@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH